Home
References
  1. Aisen PS. Anti-inflammatory Agents in Alzheimer’s Disease. Curr Neurol Neurosci Rep 2002; 2:405–409.
  2. Allen NHP, Burns A. The noncognitive features of dementia. Rev Clin Gerontol 1995; 5:57–75.
  3. Alexopoulos GS, Meyers BS, Young RC at al. The course of geriatric depression with ‘reversible dementia’: a controlled study. Am J Psychiatry 1993; 150:1693–1699.
  4. Alexopoulos GS, Abrams RC, Young RC at al. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23:271–284.
  5. Alexopoulos GS, Silver JM, Kahn at al. (eds). The Expert Consensus Guidelines Series: Agitation in Older Persons with Dementia. A postgraduate medicine special report. New York: McGraw-Hill; 1998.
  6. American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. Am J Psychiatry 1999; 156: 1–20.
  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington DC: American Psychiatric Association; 1994.
  8. Ballard CG, Bannister CL, Oyebode F. Depression in dementia sufferers. Int J Geriatr Psychiatry 1996; 11:507–515.
  9. Ballard CG, Patel A, Solis M at al. A one-year follow-up study of depression in dementia sufferers. Br J Psychiatry 1996; 168:287–291.
  10. Baltes MM, Wahl HW. The dependent-support script in institutions: Generalization to community settings. Psychology and Ageing 1992; 7:409–418.
  11. Baltes MM, Neumann E, Zank S. Maintenance and rehabilitation of independence in old age: An intervention programme for staff. Psychology and Ageing 1994; 9:179–188.
  12. Beck C, Heacock P, Mercer SO at al. Improving dressing behaviour in cognitively impaired nursing home residents. Nursing Research 1997; 6:126–132.
  13. Beekman ATF, Copeland JRM, Prince MJ. Review of community prevalence of depression in later life [EURODEP Study]. Br J Psychiatry 1999; 174:307–311.
  14. Black S, Roman GC, Geldmacher DS at al. Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34:2323–2330.
  15. Bourgeois M, Mason LA. Memory wallet intervention in an adult day-care setting. Behaviour Intervention 1996; 11:3–18.
  16. Bosenquet N, May J, Johnson N. Alzheimer’s disease in the United Kingdom. London: Health Policy Unit, Imperial School of Medicine, 1998.
  17. Booth BM, Kirchner JE, Hamilton G at al. Diagnosing depression in the medically ill: validity of a lay-administered structured diagnostic interview. J Psychiatr Res 1998; 32:353–360.
  18. Bowers J, Jorm AF, Henderson S at al. General practitioners’ detection of depression and dementia in elderly patients. Med J Aust 1990; 153:192–196.
  19. Breitbart W, Marotta R, Platt MM at al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalised AIDS patients. Am J Psychiatry 1996; 153:231–237.
  20. Brodaty H. Low diagnostic yield in a memory disorders clinic. Int Psychogeriatr 1990; 2:149–159.
  21. Brodaty H. Think of depression: atypical presentations in the elderly. Aust Fam Physician 1993; 22:1195–1203.
  22. Brodaty H, Ames D, Snowdon J at al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134–143.
  23. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003; 51:657–664.
  24. Brodaty H, Gresham M, Luscombe G. The Prince Henry Hospital dementia caregivers' training programme. Int J Geriatr Psychiatry 1997; 12:183–192.
  25. Brodaty H, Gresham M. Effect of a training programme to reduce stress in carers of patients with dementia. BMJ 1989; 299:1375–1379.
  26. Brodaty H, Griffith D, Hadzi-Pavlovic D. A survey of dementia carers: doctors’ communications, problem behaviours and institutional care. Aus N Z J Psychiatry 1990; 24:362–370.
  27. Brodaty H, Luscombe G. Depression in persons with dementia. Int Psychogeriatr 1997; 8:609–622.
  28. Burns A, Howard R, Pettit W. Alzheimer’s disease. A medical companion. Oxford: Blackwell Science Ltd; 1995.
  29. Burns A. Treatment of noncognitive features of dementia. In: Treatment and care in old age psychiatry. Edited by Levy R, Howard R, Burns A. Petersfield, UK:Wrightson Biomedical; 1994.
  30. Callahan CM, Hendrie HC, Tierney WM. The recognition and treatment of late-life depression. A view from primary care. Int J Psychiatr Med 1996; 26:155–171.
  31. Cohen-Mansfield J, Werner P. Verbally disruptive behaviours in elderly persons: A review. Facts and Research in Gerontology. In: Dementia and Cognitive Impairments. Edited by BJ Vellas, J-H Albaredo, PJ Garry. Paris: Serdi, 1994; 73–89.
  32. Cohen-Mansfield J, Werner P. The effects of an enhanced environment on nursing home residents who pace. Gerontologist 1998; 38:199–208.
  33. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly: A conceptual review. J Am Geriatr Soc 1986; 42:192–197.
  34. Cohen-Mansfield J. Approaches to the management of disruptive behaviours. In: Interventions in dementia care: Toward improving quality of life. Edited by Lawton MP, Rubinstein RL. London: Springer; 2000.
  35. Cole MG, Yaffe MJ. Pathway to psychiatric care of the elderly with depression. Int J Geriatr Psychiatry 1996; 11:157–161.
  36. Committee on Safety of Medicines. Neuroleptic sensitivity in patients with dementia. Current Probl Pharmacovigilance 1994; 20:6.
  37. Copeland JRM, Davidson IA, Dewey ME at al. Alzheimer’s disease, other dementias, depression and pseudodementia: prevalence, incidence, and three-year outcome in Liverpool. Br J Psychiatry 1992; 161:230–239.
  38. Cummings JL. Subcortical dementia. Neuropsychology, neuropsychiatry and pathophysiology. Br J Psych 1986; 149:682–697.
  39. Cummings JL, Benson DF. Cortical dementias. In: Dementia: A Clinical Approach. Boston: Butterworth-Heinemann; 1992: 73–93.
  40. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disord 1990; 18:289–299.
  41. De Deyn PP, Rabheru K, Rasmussen A at al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:946–955.
  42. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington DC: American Psychiatric Association; 1994.
  43. Doody R, Stephens J, Beck C at al. Practice parameters: management of dementia. Neurology 2001; 56:1154–1166.
  44. Draper B. The diagnosis and treatment of depression in dementia. Psychiatr Serv 1999; 50:1151–1153.
  45. Draper B, MacCuspie-Moore C, Brodaty H. Suicidal ideation and the ‘wish to die’ in dementia: the role of depression. Age Ageing 1998; 27:503–507.
  46. Draper B, Poulos C, Cole A at al. A comparison of caregivers for elderly stroke and dementia victims. J A Geriatr Soc 1994; 42:186–191.
  47. Emery VO, Oxman TE. Update on the dementia spectrum of depression. Am J Psychiatry 1992; 149:305–317.
  48. Fawcett J. Suicidal depression and physical illness. JAMA 1972; 219:1303–1310.
  49. Fitz AG, Teri L. Depression, cognition, and functional ability in patients with Alzheimer’s disease. J Am Geriatr Soc 1994; 42:186–191.
  50. Francis J. Delirium in older patients. J Am Geriatr Soc 1992; 40:829–838.
  51. Frazer D. Psychotherapy with the cognitively impaired. In: Interventions in dementia care: Toward improving quality of life. Edited by Lawton MP, Rubinstein RL. London: Springer; 2000.
  52. Frishman WH. Are antihypertensive agents protective against dementia? A review of clinical and preclinical data. Heart Dis 2002; 4:380–386.
  53. Gallo JJ, Rabins PV, Lyketsos CG at al. Depression without sadness: functional outcomes of nondysphoric depression in later life. J Am Geriatr Soc 1997; 45:570–578.
  54. Galton CJ, Hodges JR. The spectrum of dementia and its treatment. J Coll Phys Lond 1999; 33:234–239.
  55. Gauthier S, Burns A, Pettit W. Alzheimer’s disease in primary care. London: Martin Dunitz; 1997.
  56. Girotti F, Soliveri P. Cognitive and behavioral disturbances in Parkinson’s disease. Neurol Sci 2003; 24 (Suppl 1):S30–31.
  57. Hachinski VC, Iliff LD, Zilhka E at al. Cerebral flow in dementia. Arch Neurol 1975, 32:632–637.
  58. Hodges JR, Patterson K, Oxbury S at al. Semantic dementia: progressive fluent aphasia with temporal lobe atrophy. Brain 1992; 115:1783–1806.
  59. Hofman M, Seifritz E, Krauchi K at al. Alzheimer’s disease, depression, and normal ageing: merit of simple psychomotor and visuospatial tasks. Int J Geriatr Psychiatry 2000; 15:31–39.
  60. Howard R, Ballard C, O'Brien J at al. UK and Ireland Group for Optimization of Management in dementia. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry 2001; 16:714–717.
  61. Huang W, Qiu C, Winblad B at al. Alcohol consumption and incidence of dementia in a community sample aged 75 years and older. J Clin Epidemiol 2002; 55:959–964.
  62. Inouye SK, van Dyck CH, Horwitz RI. Clarifying confusion: the confusion assessment method (a new method for detection of delirium). Ann Intern Med 1990; 113:941–948.
  63. Itil T, Fink M. Anticholinergic drug-induced delirium: experimental modification, quantitative EEG and behavioural correlations. J Nerv Ment Dis 1966; 143:492–507.
  64. Kapur N, Abbott P, Lowman A at al. The neuropsychological profile associated with variant Creutzfeldt-Jakob disease. Brain 2003; 126(Pt 12):2693-702.
  65. Karuza J, Katz P. Psychosocial interventions in long term care: A critical overview. In: Advances in long term care, volume 1. Edited by Katz PR, Kane RL, Mezey MD. London: Springer, 1991.
  66. Katz IR, Jeste DV, Mintzer JE at al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60:107–115.
  67. Kitwood T. Dementia reconsidered: The person comes first. Buckingham: Open University Press; 1997.
  68. Keefover R. The clinical epidemiology of Alzheimer’s disease. Neurology Clinics 1996; 14:337–351.
  69. Knopman DS, Mastri AR, Frey WH at al. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 1990; 40:251–256.
  70. Knopman DS, DeKosky ST, Cummings JL at al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143–1153.
  71. Knauper B, Wittchen HU. Diagnosing major depression in the elderly: evidence for response bias in standardized diagnostic reviews? J Psychiatr Res 1994; 28:147–164.
  72. Lawton MP, Rubinstein RL (Eds). Interventions in dementia care: toward improving quality of life. London: Springer Publishing Company; 2000.
  73. Linka E, Bartko G, Agardi T at al. Dementia and depression in elderly medical inpatients. Int Psychogeriatr 2000; 12:67–75.
  74. Linn RT, Wolf PA, Bachman DL at al. The preclinical phase of probable Alzheimer’s disease. Arch Neurol 1995; 52:485–490.
  75. Logsdon RG, Teri L. The pleasant Events Schedule-AD. Gerontologist 1997; 37:40–45.
  76. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; (2):CD002852.
  77. Lyketsos CG, Steele C, Galik at al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry 1999; 156:66–71.
  78. Lyketsos CG, Sheppard JM, Steele CD at al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’s disease: initial results from the Depression in Alzheimer’s Disease Study. Am J Psychiatry 2000; 157:1686–1689.
  79. Lyness JM, Cox C, Curry J at al. Older age and the under-reporting of depressive symptoms. J Am Geriatr Soc 1995; 43:216–221.
  80. Mackenzie TB, Robiner WN, Knopman DS. Differences between patient and family assessments of depression in Alzheimer’s disease. Am J Psychiatry 1989; 146:1174–1178.
  81. Maletta G. Management of behaviour problems in elderly patients with Alzheimer’s disease and other dementias. Clin Geriatr Med 1988; 4:719–747.
  82. Marksteiner J, Bodner T, Gurka P. Alcohol-induced cognitive disorder: alcohol dementia. Wien Med Wochenschr 2002; 152:98–101 [in German].
  83. Martindale JL, Geschwind MD, Miller BL. Psychiatric and neuroimaging findings in Creutzfeldt-Jakob disease. Curr Psychiatry Rep 2003; 5:43–46.
  84. Masters CL, Harris JO, Gajdusek DC at al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979; 5:177–188.
  85. Melzer D, Ely M, Brayne C. Cognitive impairment in elderly people: population based estimated of future in England, Scotland, Wales. BMJ 1997; 315:462.
  86. McKeith I, Fairbairn A, Perry R at al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305:673–678.
  87. McKeith IG, Galasko D, Kosaka K at al. Consensus guidelines for the clinical and pathological doagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB International Workshop. Neurology 1996; 47:1113–1124.
  88. McKhann G, Drachman D, Folstein MF at al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34:939–944.
  89. Mirra SS, Heyman A, McKeel D at al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer’s disease. Neurology 1991; 41:479–486.
  90. Mitchell P. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997; 17:390–406.
  91. Mittelman MS, Ferris SH, Shulman E at al. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 1996; 276:1725–1731.
  92. Morris JC. Evaluation of the demented patient. In: Handbook of Dementing Illnesses. Edited by JC Morris. New York: Marcel Dekker, 1994; 71–84.
  93. National Institute for Clinical Excellence. Technology Appraisal Guidance No. 19, January 2001.
  94. Neary D, Snowden JS, Gustafson L at al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51:1546–1554.
  95. Nyth AL, Gottfries CG, Lyby K at al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992; 86:138–145.
  96. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990; 157:894–901.
  97. O’Keeffe ST. Clinical subtypes of delirium in the elderly. Dement Geriatr Cogn Disord 1999; 10:380–385.
  98. Perl DP. Neuropathology of Alzheimer’s disease and related disorders. Neurol Clin 2000; 18:847–864.
  99. Perry RH, Irving D, Blessed G at al. Senile dementia of Lewy body type – a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990, 95:119–139.
  100. Petersen RC, Smith GE, Waring SC at al. Mild cognitive impairment: clinical characterisation and outcome. Arch Neurol 1999; 56:303–308.
  101. Plassman B, Breitner J. The genetics of Alzheimer’s disease. In: Dementia 2nd Edition. Edited by J O’Brien, D Ames and A Burns. Arnold, 2000.
  102. Poirier J, Davignon J, Bouthillier D at al. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993; 342:697–699.
  103. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999; 175:12–16.
  104. Poser S, Mollenhauer B, Kraubeta A at al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999; 122:2345–2351.
  105. Pryse-Phillips W, Galasko D. Non-Alzheimer dementias. In: Clinical Diagnosis and Management of Alzheimer’s Disease. Edited by S Gauthier. London: Martin Dunitz, 1996; 51–70.
  106. Rabinovich B, Cohen-Mansfield J. The impact of participation in structured recreational activities on the agitated behaviour of nursing residents: An observational study. Activities, Adaptation and Ageing 1992; 16:18–98.
  107. Reisberg B, Doody R, Stöffler A at al. Memantine in moderate-to-severe Alzheimer's disease. New Engl J Med 2003; 348:1333–1341.
  108. Reisberg B, Windscheif U, Ferris S at al. Memantine in moderately severe to severe Alzheimer’s disease: results of a placebo controlled 6 month study. Neurobiol Aging 2000; 21(suppl1):S275 [Abstract].
  109. Reisberg B, Ferris S, DeLeon M at al. The Global Deterioration Scale (GDS) for the assessment of primary degenerative dementia. Am J Psych 1982; 139:1136–1139.
  110. Reifler BV, Teri L, Raskind M at al. Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression. Am J Psychiatry 1989; 146:45–49.
  111. Ritchie K, Kildare D. Senile dementia, age related or ageing related? Lancet 1995; 346:931–934.
  112. Roose SP, Glassman AH, Attia E at al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151:1735–1739.
  113. Roman GC, Tatemichi TK, Erkinjuntti T at al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250–260.
  114. Rosenquist K, Tariot P, Loy R. Treatments for behavioural and psychological symptoms in Alzheimer’s disease and other dementias. In: Dementia, second edition. Edited by O’Brien J, Ames D and Burns A. London: Arnold; 2000, 571–601.
  115. Roth M, Mountjoy CQ, Amrein R at al. Moclobemide in elderly patients witrh cognitive decline and depression. An international double-blind, placebo-controlled study. Br J Psychiatry 1996; 168:149–157.
  116. Rovner BW, Steele CD, Shmuely Y at al. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc 1996; 44:7–13.
  117. Sano M. Prevention of Alzheimer’s disease: Where we stand. Curr Neuro NeuroSci Rep 2002; 2:392–399.
  118. Sachdev PS, Smith JS, Angus-Lepan H at al. Pseudodementia twelve years on. J Neurol Neurosurg Psychiatry 1990; 53:254–259.
  119. Schumock G. Economic considerations in the treatment and management of Alzheimer’s disease. Am J Health Syst Pharm 1998; 55(suppl 2):S17–S21.
  120. Seux ML. Antihypertensive treatment and prevention of dementia. Ann Cardiol Angeiol (Paris). 1999; 48:512–517 [in French].
  121. Shah S, Harris M. A survey of general practitioners’ confidence in their management of elderly patients. Aust Fam Physician 1997; 26(suppl 1):S12–S17.
  122. Snowdon DA, Greiner LH, Mortimer JA at al. Brain infarction and the clinical expression of Alzheimer’s disease. JAMA 1997; 277:813–817.
  123. Spector A, Orrell M, Davies S at al. Reality orientation for dementia. The Cochrane Library, 1999; Issue 3, Oxford: Update Software.
  124. Spector A, Orrell M, Davies S at al. Reminiscence therapy for dementia. The Cochrane Library , 1999; Issue 4, Oxford: Update Software.
  125. Stoudemire A, Hill CD, Morris R at al. Long-term affective and cognitive outcome in depressed older adults. Am J Psychiatry 1993; 150:896–900.
  126. Taragano FE, Lyketsos CG, Mangone CA at al. A double-blind, randomised, fixed-dose trial of fluoxetine versus amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics 1997; 38:246–252.
  127. Tariot PN, Erb R, Leibovici A at al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42:1160–1166.
  128. Teri L, Logsdon RG, Uomoto J at al. Behavioural treatment of depression in dementia patients: A controlled clinical trial. J Gerontol 1997; 52B:P159–P166.
  129. Teri L and Logsdon R. Identifying pleasant activities for Alzheimer’s patients: The Pleasant Events Schedule-AD. Gerontologist 1991; 31:124–127.
  130. Truelsen T, Thudium D, Gronbaek M; Copenhagen City Heart Study. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002; 59:1313-1319.
  131. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res 1988; 23:89–97.
  132. Trzepacz PT, Wise MG. Neuropsychiatric Aspects of Delirium. In: The American Psychiatric Press textbook of neuropsychiatry, 3rd edition. Edited by SC Yudofsky, RE Hales. Washington, DC: American Psychiatric Press, 1997;447–470.
  133. Visser PJ, Verhey FR, Ponds RW at al. Distinction between preclinical Alzheimer’s disease and depression. J Am Geriatr Soc 2000; 48:479–484.
  134. Volicer L, Rheaume Y, Cyr D. Treatment of depression in advanced Alzheimer’s disease using sertraline. J Geriatr Psychiatry Neurol 1994; 7:227–229.
  135. Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST study. (Benefit and efficacy in Severely Demented Patients during Treatment with Memantine). Int J Geriatr Psychiatry 1999; 14:135–146.
  136. Wisniewski T, Sigurdsson EM. Immunization Treatment Approaches in Alzheimer’s disease and Prion Diseases. Curr Neurol Neurosci Rep 2002; 2:400–404.
  137. Williams MA, Ward SE, Campbell EB. Confusion: testing versus observation. J Gerontol Nurs 1988; 14:25–30.
  138. Woods RT. Discovering the person with AD: cognitive, emotional and behavioural aspects. Aging Ment Health 2001; 5(Suppl 1):S7–S16.
  139. Woods RT, Ashley J. Simulated presence therapy: Using selected memories to manage problem behaviours in Alzheimer’s disease patients. Geriatric Nursing 1995: 16:9–14.
  140. Woods R. Non-pharmacological Techniques. In: Evidence-based Dementia Practice. Edited by N Qizilbash, L Schneider, H Chui at al. Oxford: Blackwell Science Ltd; 2002.
  141. Woods R, Bird M. Non-pharmacological approaches to treatment. In: Diagnosis and management of dementia: A manual for memory disorder teams. Edited by GW Wilcock, RS Bucks and K Rockwood. New York, NY: Oxford University Press; 1999.
  142. Yale R. Developing support groups for individuals with early stage AD: planning, implementation and evaluation. Baltimore: Health Profession Press; 1995.
  143. Yesavage JA, Brink TL, Rose TL at al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17:37–49.
  144. Zuccala G, Onder G, Pedone C at al.; Gruppo Italiano di Farmacoepidemiologia nell’Anziano Investigators. Dose-related impact of alcohol consumption on cognitive function in advanced age: results of a multicenter survey. Alcohol Clin Exp Res 2001; 25:1743–1748.